m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00186)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
ATG12
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3 | ||
Cell Line | Mouse testis | Mus musculus |
Treatment: Mettl3 knockout mouse testis
Control: Mouse testis
|
GSE99771 | |
Regulation |
|
logFC: -2.94E+00 p-value: 6.14E-05 |
More Results | Click to View More RNA-seq Results | |
Representative RIP-seq result supporting the interaction between ATG12 and the regulator | ||
Cell Line | MDA-MB-231 | Homo sapiens |
Regulation | logFC: 1.85E+00 | GSE60213 |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | METTL3 can sensitise hepatocellular carcinoma cells to sorafenib through stabilising forkhead box class O3 (FOXO3) in an m6A-dependent manner and translated by YTHDF1, thereby inhibiting the transcription of autophagy-related genes, including ATG3, ATG5, ATG7, Ubiquitin-like protein ATG12 (ATG12), and ATG16L1. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12.02 | ||
Responsed Drug | Sorafenib | Approved | ||
Pathway Response | FoxO signaling pathway | hsa04068 | ||
Autophagy | hsa04140 | |||
Cell Process | Cell autophagy | |||
YTH domain-containing family protein 1 (YTHDF1) [READER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | METTL3 can sensitise hepatocellular carcinoma cells to sorafenib through stabilising forkhead box class O3 (FOXO3) in an m6A-dependent manner and translated by YTHDF1, thereby inhibiting the transcription of autophagy-related genes, including ATG3, ATG5, ATG7, Ubiquitin-like protein ATG12 (ATG12), and ATG16L1. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12.02 | ||
Responsed Drug | Sorafenib | Approved | ||
Pathway Response | FoxO signaling pathway | hsa04068 | ||
Autophagy | hsa04140 | |||
Cell Process | Cell autophagy | |||
Liver cancer [ICD-11: 2C12]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | METTL3 can sensitise hepatocellular carcinoma cells to sorafenib through stabilising forkhead box class O3 (FOXO3) in an m6A-dependent manner and translated by YTHDF1, thereby inhibiting the transcription of autophagy-related genes, including ATG3, ATG5, ATG7, Ubiquitin-like protein ATG12 (ATG12), and ATG16L1. | |||
Responsed Disease | Hepatocellular carcinoma [ICD-11: 2C12.02] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Sorafenib | Approved | ||
Pathway Response | FoxO signaling pathway | hsa04068 | ||
Autophagy | hsa04140 | |||
Cell Process | Cell autophagy | |||
Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | METTL3 can sensitise hepatocellular carcinoma cells to sorafenib through stabilising forkhead box class O3 (FOXO3) in an m6A-dependent manner and translated by YTHDF1, thereby inhibiting the transcription of autophagy-related genes, including ATG3, ATG5, ATG7, Ubiquitin-like protein ATG12 (ATG12), and ATG16L1. | |||
Responsed Disease | Hepatocellular carcinoma [ICD-11: 2C12.02] | |||
Target Regulator | YTH domain-containing family protein 1 (YTHDF1) | READER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Sorafenib | Approved | ||
Pathway Response | FoxO signaling pathway | hsa04068 | ||
Autophagy | hsa04140 | |||
Cell Process | Cell autophagy | |||
Sorafenib
[Approved]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | METTL3 can sensitise hepatocellular carcinoma cells to sorafenib through stabilising forkhead box class O3 (FOXO3) in an m6A-dependent manner and translated by YTHDF1, thereby inhibiting the transcription of autophagy-related genes, including ATG3, ATG5, ATG7, Ubiquitin-like protein ATG12 (ATG12), and ATG16L1. | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12.02 | ||
Pathway Response | FoxO signaling pathway | hsa04068 | ||
Autophagy | hsa04140 | |||
Cell Process | Cell autophagy | |||
Experiment 2 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | METTL3 can sensitise hepatocellular carcinoma cells to sorafenib through stabilising forkhead box class O3 (FOXO3) in an m6A-dependent manner and translated by YTHDF1, thereby inhibiting the transcription of autophagy-related genes, including ATG3, ATG5, ATG7, Ubiquitin-like protein ATG12 (ATG12), and ATG16L1. | |||
Target Regulator | YTH domain-containing family protein 1 (YTHDF1) | READER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12.02 | ||
Pathway Response | FoxO signaling pathway | hsa04068 | ||
Autophagy | hsa04140 | |||
Cell Process | Cell autophagy | |||